Benzoyl Peroxide (Bepio Gel)
Bactericidal oxidizing agent eradicating acne bacteria with no risk of antibiotic resistance
About This Treatment
Benzoyl peroxide (BPO) 2.5% gel (Bepio) has been insurance-covered in Japan since 2015. Directly kills C. acnes through free oxygen radical generation, with the critical advantage of no antibiotic resistance development. Also provides keratolytic and comedolytic effects. Rated recommendation A in Japanese guidelines. Available in combination with adapalene (Epiduo) and clindamycin (Duac).
Mechanism of Action
BPO decomposes on skin to release benzoic acid and reactive oxygen species (free radicals): ①oxidatively destroys C. acnes cell membranes (anaerobic bacteria with weak oxygen defense), ②loosens intercorneocyte bonds for keratolysis (comedolytic), ③oxidizes follicular lipids altering sebum composition. No resistance because non-specific oxidation cannot be adapted to by bacteria.
Indications
Expected Results
Inflammatory lesion reduction starts at 2-4 weeks. Japanese clinical trial: 80% median reduction in inflammatory acne lesions at 12 weeks. Adapalene combination (Epiduo) achieves faster and greater improvement than monotherapy. Also effective on non-inflammatory lesions.
Clinical Evidence
Risks & Side Effects
Initial dryness, peeling, erythema, burning (common, subsides in 2-4 weeks). Contact dermatitis risk (patch test recommended). CAUTION: bleaches fabrics/towels/pillowcases. Avoid eyes/mouth/mucosa. Moisturizer improves tolerability. Rare allergic contact dermatitis.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition